Precision Biosciences Says USPTO to Reexamine Additional Cellectis Patents | GenomeWeb

NEW YORK (GenomeWeb News) – Precision Biosciences said today that the US Patent and Trademark Office has granted the firm's request to reexamine a pair of US patents that Cellectis has asserted against Precision in ongoing patent-infringement litigation.

The patents, US Nos. 6,610,545 and 7,309,605, deal with DNA vectors that can be used in gene mapping and site-directed gene insertion. Cellectis has a license to the patents, which are owned by the Institut Pasteur and Universite Pierre et Marie Curie.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.